DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Summary for Patent: RE46965
|Title:||Intermediates for the preparation of analogs of Halichondrin B|
|Abstract:||The present invention provides macrocyclic compounds, synthesis of the same and intermediates thereto. Such compounds, and compositions thereof, are useful for treating or preventing proliferative disorders Formula (F-4). ##STR00001##|
|Inventor(s):||Austad; Brian (Tewksbury, MA), Chase; Charles E. (Londonderry, NH), Fang; Francis G. (Andover, MA), Calkins; Trevor (Stoughton, WI), Lewis; Bryan M. (North Brunswick, NJ)|
|Assignee:||Eisai R&D Management Co., Ltd. (Tokyo, JP)|
1. A compound of formula F-4: ##STR00154## wherein: each of PG.sup.1, PG.sup.2, and PG.sup.3 is independently hydrogen or a suitable hydroxyl protecting group; R.sup.1 is R or
--OR; each R is independently hydrogen, C.sub.1-4 haloaliphatic, benzyl, or C.sub.1-4 aliphatic; and LG.sup.1 is a suitable leaving group..].
.[.2. The compound according to claim 1, wherein said compound is of formula F-4': ##STR00155## .].
.[.3. The compound according to claim 2, wherein R.sup.1 is OR wherein R is hydrogen, methyl, or benzyl..].
.[.4. The compound according to claim 2, wherein PG.sup.1 and PG.sup.2 are both hydrogen..].
.[.5. The compound according to claim 2, wherein each of PG.sup.1 and PG.sup.2 is independently a suitable hydroxyl protecting group..].
.[.6. The compound according to claim 5, wherein one or both of PG.sup.1 and PG.sup.2, taken together with the oxygen atom to which each is bound, is a silyl ether or an arylalkyl ether..].
.[.7. The compound according to claim 6, wherein PG.sup.1 and PG.sup.2 are both t-butyldimethylsilyl..].
.[.8. The compound according to claim 5, wherein PG.sup.1 and PG.sup.2 are taken together, with the oxygen atoms to which they are bound, to form a diol protecting group..].
.[.9. The compound according to claim 8, wherein said diol protecting group is a cyclic acetal or ketal, a silylene derivative, a cyclic carbonate, or a cyclic boronate..].
.[.10. The compound according to claim 2, wherein LG.sup.1 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, or halogen..].
.[.11. The compound according to claim 10, wherein LG.sup.1 is mesyloxy tosyloxy, chloro, iodo, bromo, or triflate..].
.[.12. The compound according to claim 2, wherein said compound is: ##STR00156## .].
.[.13. The compound according to claim 1, wherein said suitable hydroxyl protecting group, taken with the oxygen atom to which it is bound, is selected from an ester, an ether, a silyl ether, an alkyl ether, an arylalkyl ether, and an alkoxyalkyl ether..].
.[.14. The compound according to claim 13, wherein said ester is a formate, acetate, carbonate, or sulfonate; said silyl ether is a trialkylsilyl ether; or said alkoxyalkyl ether is an acetal..].
.[.15. The compound according to claim 13, wherein said ester is formate, benzoyl formate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetyl), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate, methyl carbonate, 9-fluorenylmethyl carbonate, ethyl carbonate, 2,2,2-trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, 2-(phenylsulfonyl)ethyl carbonate, vinyl carbonate, ally! carbonate, or p-nitrobenzyl carbonate; said silyl ether is trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, or triisopropylsilyl ether; said alkyl ether is methyl, trityl, t-butyl, allyl, or allyloxycarbonyl ether; said alkoxyalkyl ether is methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, beta-(trimethylsilyl)ethoxymethyl, and tetrahydropyranyl ethers; or said arylalkyl ether is benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2- picolyl, or 4-picolyl..].
.[.16. The compound according to claim 1, wherein LG.sup.1 is mesyloxy or tosyloxy..].
.[.17. The compound according to claim 9, wherein said cyclic acetal or ketal is methylene, ethylidene, benzylidene, isopropylidene, cyclohexylidene, or cyclopentylidene; or said silylene derivative is di-t-butylsilylene or a 1,1,3,3-tetraisopropyldisiloxanylidene derivative..].
.[.18. The compound according to claim 1, wherein LG.sup.1 is sulphonyloxy, optionally substituted alkylsulphonyloxy, optionally substituted alkenylsulfonyloxy, optionally substituted arylsulfonyloxy, or halogen..].
.Iadd.19. A compound of formula: ##STR00157## and/or a pharmaceutically acceptable salt thereof..Iaddend.
.Iadd.20. A composition comprising a compound: ##STR00158## and/or a pharmaceutically acceptable salt thereof, and a compound of formula: ##STR00159## and/or a pharmaceutically acceptable salt thereof..Iaddend.
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.